AMA CPT® Assistant - 2012 Issue 4 (April)
Coding Clarification: Administration/Monitoring of Oral Multiple Sclerosis Treatment Therapy (April 2012)
April 2012 page 10 Coding Clarification: Administration/Monitoring of Oral Multiple Sclerosis Treatment Therapy We have received questions about whether the prolonged services evaluation and management (E/M) codes (99354 and 99355) may be reported when providing extended office or other outpatient vital signs monitoring services associated with the oral administration of fingolimod, a disease modifying therapy, for long-term treatment of relapsing subtypes of multiple sclerosis in adults. Although the protocol for administration of this drug may require prolonged monitoring of the patient's vital signs (eg, every 30 to 60 minutes for up to 6 hours) to assess bradycardia following oral...
Subscribe or sign in to view the full article.
Article Overview
This April 2012 coding clarification discusses how to think about office-based monitoring and administration services associated with an oral therapy for multiple sclerosis. It explains the general categories of E/M and prolonged service reporting that may come into play, notes the absence of a specific CPT code for the monitoring service described, and mentions that payer-specific guidance may affect reporting choices. The article is useful for physicians, office staff, and coding professionals who handle outpatient drug monitoring and related documentation.
Why This Topic Matters
Accurate reporting for outpatient therapy monitoring can affect compliance, documentation quality, and claim acceptance. This clarification helps readers understand the scope of available coding pathways and the role of payer policy in these scenarios.
Article Sections
-
Coding Clarification: Administration/Monitoring of Oral Multiple Sclerosis Treatment Therapy
Introduces the outpatient monitoring scenario for an oral multiple sclerosis therapy and frames the coding question addressed in the article.
-
Monitoring and prolonged service considerations
Summarizes the general reporting context for extended vital-signs monitoring and the relationship to office or other outpatient E/M reporting. It also addresses prolonged service concepts in the setting described.
-
Payer guidance and other reporting approaches
Describes that some payers may provide specific guidance for these situations and that alternative reporting approaches may be considered depending on payer requirements.
-
Drug supply reporting and HCPCS considerations
Discusses reporting of the drug itself and notes a broad HCPCS consideration related to orally administered medications.
What You Will Learn
- How the article frames outpatient monitoring for an oral multiple sclerosis therapy
- Which general categories of E/M and prolonged service reporting are discussed
- Why payer-specific guidance may matter in this scenario
- How the article approaches reporting of the drug supply and related coding categories
Who Should Read This
- Physician office coders
- Outpatient billing staff
- Compliance and reimbursement staff
- Neurology practice administrators
- Healthcare professionals responsible for documentation and charge capture
Codes Discussed
Code Ranges Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com
